Supplementing with resveratrol improves blood glucose level in people with Type 2 diabetes

Researchers at Tehran University of Medical Sciences in Iran report that supplementing with resveratrol can help people with Type 2 diabetes improve their blood sugar levels. In their study, they looked at the effect of resveratrol supplementation on the blood sugar level and inflammatory markers in people with Type 2 diabetes.

• Chronic low-grade inflammation is a characteristic of Type 2 diabetes.
• In lab and animal studies, resveratrol has been shown to exhibit anti-inflammatory effects.
• However, clinical trials addressing these effects in people with Type 2 diabetes are limited.
• For the current study, the Iranian researchers hypothesized that supplementation with resveratrol might improve inflammatory markers in people with Type 2 diabetes.
• To test their hypothesis, they conducted a randomized, double-blind, placebo-controlled clinical trial.
• They recruited 45 individuals with Type 2 diabetes and supplemented them with either 800 milligrams (mg) per day of resveratrol or placebo capsules for eight weeks.
• The researchers measured inflammatory markers at the start and the end of the study.
• They found that resveratrol supplementation did not affect diabetes inflammatory markers.
• However, they discovered that resveratrol supplementation led to significant reductions in the levels of fasting blood glucose and blood pressure.
• These results indicate that resveratrol may not improve inflammatory markers in people with Type 2 diabetes, but may reduce their fasting blood glucose and blood pressure.

These findings, which were published in the journal Nutrition Research, suggest that an eight-week supplementation with resveratrol can help reduce levels of blood glucose and blood pressure in people with Type 2 diabetes.

To read more studies on natural diabetes treatments, visit DiabetesCure.news.

Journal Reference:
Khodabandehloo H, Seyyedebrahimi S, Esfahani EN, Razi F, Meshkani R. RESVERATROL SUPPLEMENTATION DECREASES BLOOD GLUCOSE WITHOUT CHANGING THE CIRCULATING CD14 + CD16 + MONOCYTES AND INFLAMMATORY CYTOKINES IN PATIENTS WITH TYPE 2 DIABETES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. Nutrition Research. June 2018; 54: 40-51. DOI: 10.1016/j.nutres.2018.03.015